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In 2010, the World Health Organization (WHO) en-dorsed Xpert® MTB/RIF (Cepheid, Inc, Sunnyvale, 
CA, USA), an automated, rapid, polymerase chain re-
action (PCR) based diagnostic assay for tuberculosis 
(TB).1 Although numerous clinical trials and studies 
have shown that Xpert has high sensitivity and speci-
ficity for the diagnosis of TB and detection of rifampi-
cin (RMP) resistance,2–7 it is important to assess its uti-
lization in routine program settings, given the many 
logistical and health systems barriers that may influ-
ence the impact of Xpert on patient care.5,8–10
In 2011, Cambodia’s National Center for Tubercu-
losis and Leprosy Control (CENAT) committed to in-
troducing Xpert into routine practice to improve TB 
diagnosis among prioritized populations.11 In accor-
dance with WHO recommendations, the initial im-
plementation of Xpert in Cambodia focused on peo-
ple living with the human immunodeficiency virus/
acquired immune-deficiency syndrome (HIV/AIDS, 
PLHA) presumed to have TB and those presumed to 
have multidrug-resistant (MDR) TB, recommending 
Xpert as the initial diagnostic test for both 
populations.12,13
Cambodia has been designated a high TB burden 
country, with a TB incidence rate of 411 per 100 000 
population. While 6.3% of persons with TB are 
HIV-infected, Cambodia has a relatively low HIV prev-
alence among all adults, of 0.7%.14–16 In addition to 
scaling up access to Xpert for these designated popula-
tions, several active case-finding (ACF) projects have 
incorporated Xpert for testing contacts of TB patients 
and conducting community-wide TB screening.17–19
The US Centers for Disease Control and Prevention 
(CDC, Atlanta, GA, USA) and CENAT evaluated the 
rollout of Xpert in routine programmatic settings for 
the diagnosis of TB among PLHA in preparation for 




This evaluation was conducted in four provinces in 
northwest Cambodia (Battambang, Bantay Meanchey, 
Pailin and Pursat), and included routinely collected 
national program data for all PLHA seen at a TB clinic 
in the catchment area from March to December 2012. 
With a population of 2.2 million, these provinces 
comprise approximately 16% of Cambodia’s popula-
tion.20 During the evaluation period, 7612 PLHA were 
receiving care at HIV clinics in the catchment area.21,22 
These provinces were selected by CENAT for initial 
Xpert rollout, given pre-existing laboratory capacity at 
Battambang Provincial Referral Hospital (PRH) and es-
tablished networks within these four provinces of 
specimen referral to the Battambang PRH laboratory 
for TB culture. In these four provinces, we included 
eight operational districts, each with a district referral 
hospital or PRH housing a TB clinic. The nine HIV 
clinics distributed throughout these eight districts rou-
tinely refer patients presumed to have TB to the co-lo-
cated TB clinic for diagnostic evaluation (Figure). 
Xpert machines were placed at the Battambang PRH, 
which also provides TB culture services for the region, 
and the Mongkol Borei PRH to provide Xpert testing 
services to the four provinces.11
Design and methods
CENAT, the CDC, and other partners modified the re-
cording and reporting tools and developed new diag-
nostic algorithms to incorporate Xpert for diagnosing 
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Objective: To describe the implementation and utilization 
of the Xpert® MTB/RIF (Xpert) assay to diagnose tubercu-
losis (TB) among people living with the human immuno-
deficiency virus/acquired immune-deficiency syndrome 
(HIV/AIDS, PLHA) in Cambodia.
Design: Following the rollout of Xpert, an evaluation 
was conducted in four provinces of Cambodia from 
March to December 2012 to determine the utilization, 
performance, and turnaround time (TAT) of Xpert among 
PLHA. Data were collected from paper-based patient 
registers.
Results: Of 497 PLHA with a positive TB symptom 
screen, 357 (72%) were tested with smear microscopy, 
and 250 (50%) with Xpert; 25 (10%) PLHA tested with 
Xpert were positive for TB and none were rifampicin-re-
sistant. The utilization of Xpert increased from 23% to 
75%, with a median TAT of 1 day. Across districts, utiliza-
tion ranged from zero to 85%, while the TAT ranged 
from zero to 22 days.
Conclusion: While early data show increasing utilization 
of Xpert for PLHA with a positive symptom screen, most 
patients underwent smear microscopy as an initial diag-
nostic test. Training delays and challenges associated 
with specimen referral may have contributed to variabil-
ity in Xpert uptake and TAT, particularly for sites without 
onsite Xpert testing. Enhanced programmatic support, 
particularly for specimen referral and results reporting, 
may facilitate appropriate utilization.
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TB among PLHA presumed to have TB. Since 2010, national 
guidelines for PLHA have required screening for TB at monthly 
HIV clinic visits based on the presence of any fever, cough, weight 
loss, or 2 weeks of drenching night sweats. Guidelines recom-
mend that patients with a positive symptom screen be referred to 
the TB clinic for a diagnostic evaluation.23 Prior to Xpert rollout, 
diagnostic evaluation of PLHA with a positive symptom screen in-
cluded a clinical evaluation, smear microscopy of three sputum 
specimens, chest radiograph (CXR), and TB culture if the patient 
was smear-negative. Most district facilities had smear microscopy 
and CXR on site, while TB culture was only available at Battam-
bang PRH and CENAT’s central laboratory. Under the new algo-
rithms developed for the rollout of Xpert, eligible PLHA were to 
undergo a clinical evaluation, CXR, and Xpert on a single sputum 
specimen to replace smear microscopy. While CXR could still be 
performed at the district health facilities, Xpert was only available 
at Battambang and Mongkol Borei PRHs. According to the new 
algorithm, culture and drug susceptibility testing were performed 
only if RMP resistance was detected on the initial Xpert result. 
Specimens were collected from patients at the district health facil-
ities and transported to the nearest PRH by district staff or courier. 
The distance from the Xpert testing to district health facilities 
ranged from 25 to 146 km, from Thmar Khoul and Sampov Loun, 
respectively.
Laboratory staff were trained in the use of Xpert modules and 
cartridges, specimen handling, management of invalid or error re-
sults, new recording and reporting tools, and the interpretation of 
results. Program staff, district and provincial TB program manag-
ers, and clinicians were trained in the new diagnostic algorithm 
and procedures for specimen referral.
Delays in procurement and calibration of one of the two Xpert 
machines led to staggered placement. On 21 February 2012, an 
Xpert machine was placed at the Battambang PRH, which pro-
vides TB culture services to all four northwest provinces. On 6 
June 2012, a second Xpert machine was placed at the Mongkol 
Borei PRH laboratory, which had previously only performed 
smear microscopy. Collectively, these laboratories provided Xpert 
testing services for all eight districts.
Data sources
We collected data from three paper-based patient registers located 
at different levels of the health system to capture data on the di-
agnostic evaluation and treatment for PLHA eligible for Xpert. 
Several paper-based registers were newly introduced or modified 
for Xpert rollout in early 2012: 1) PLHA TB Suspect Registers at TB 
clinics co-located with HIV clinics to document the evaluation of 
symptom screen-positive PLHA, 2) pre-existing TB Treatment Reg-
isters at district level to capture TB treatment data for PLHA, and 
3) TB Laboratory Registers modified to incorporate Xpert testing 
for PLHA.
Data collection and analysis
Data were collected retrospectively from paper-based registers for 
patients registered from March to December 2012. Register pages 
were photographed, and the photos were uploaded to a secure, 
password-protected computer. Patient-level data were entered 
into two password-protected databases which were reconciled to 
minimize entry errors. Patients were assigned a unique study ID 
after linking patient entries across program registers using name, 
age, sex, and address. The analytic data set contained no patient 
identifiers. Turnaround time (TAT) was defined as the interval be-
tween the date of TB screening, at which point a specimen for 
Xpert testing should have been collected, and the date the health 
facility received the Xpert test result. Data were analyzed using 
SAS 9.3 (Statistical Analysis Institute, Cary, NC, USA).
Ethics approval
The evaluation was reviewed by both the CDC and the director of 
CENAT. The CDC and CENAT determined the study to be a pro-
gram evaluation and not research involving human participants; 
institutional review board approval was therefore not required.
FIGURE TB-HIV co-located facilities and provincial referral hospitals in evaluation 
provinces and districts in Cambodia. • = TB-HIV collocated facilities;  = provin-
cial referral hospitals; TB = tuberculosis; HIV = human immunodeficiency virus.
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RESULTS
Between 1 March and 31 December 2012, 497 PLHA with a posi-
tive symptom screen were recorded in the PLHA TB Suspect Regis-
ters in the four provinces. Approximately half of those registered 
were male, with a median age of 37 years (IQR 32–45), and 235 
(47%) PLHA were on antiretroviral therapy (ART). Among pa-
tients who reported symptoms, 357 (72%) reported cough, 409 
(82%) reported fever, 240 (48%) reported weight loss and 200 
(40%) reported 2 weeks of night sweats (Table 1).
Xpert testing was performed for 250 (50%) of the 497 PLHA 
with a positive symptom screen; of those tested, 25 (10%) were 
positive for Mycobacterium tuberculosis (Table 2). Only 17 (3%) 
PLHA underwent Xpert as the initial diagnostic test in accordance 
with national guidelines. Smear microscopy was performed for 
357 (72%) of the PLHA with a positive symptom screen, of whom 
31 (9%) were smear-positive. Of the 353 (71%) PLHA who had a 
CXR, 103 (29%) had findings consistent with TB according to the 
reviewing clinician. Only 22 (4%) PLHA had a sputum culture 
performed, of whom four (18%) were positive for M. tuberculosis 
and six (27%) were positive for non-tuberculous mycobacteria 
(NTM). Of the PLHA with a positive symptom screen, 65 (13%) 
had no documented result for Xpert, smear microscopy, CXR or 
culture. Of those with no diagnostic evaluation recorded, one 
(2%) was diagnosed with smear-negative TB and six (9%) with ex-
tra-pulmonary TB (EPTB). Of the 25 Xpert tests positive for M. tu-
berculosis, 24 (96%) were susceptible to RMP, and one had an in-
determinate result for RMP resistance (Table 3). All patients with a 
positive Xpert result were diagnosed with pulmonary TB (PTB). 
Only three (1%) Xpert tests were reported as invalid or indetermi-
nate for M. tuberculosis.
The proportion of PLHA with a positive symptom screen who 
underwent Xpert testing increased from 23% in the second quarter 
to, respectively, 75% and 73% in the third and fourth quarters. The 
proportion of PLHA tested with Xpert varied by district, ranging 
from zero to 85% (Table 4). The median TAT from clinic visit to re-
ceipt of Xpert result was 1 day, although this ranged from zero to 
22 days. Two sites were co-located with a laboratory performing 
Xpert testing; one had a median TAT of 0 days, while the other had 
a median TAT of 7 days. Delays in collecting specimens from pa-
tients and lack of real-time results reporting contributed to this de-
lay. Sites that were not co-located had a median TAT of 12 days.
In program registers, a ‘final diagnosis’ indicates a clinical deci-
sion and patient classification based on pre-defined categories (TB 
ruled out, smear-positive PTB, smear-negative PTB and EPTB). A 
final diagnosis was recorded for 417 (84%) PLHA with a positive 
symptom screen, of whom 123 (29%) were diagnosed with any 
form of TB. Among PLHA diagnosed with TB, 34 (28%) were re-
corded as smear-positive PTB, 63 (51%) as smear-negative PTB 
and 26 (21%) as EPTB.
Among 417 PLHA with a positive symptom screen and a final 
diagnosis, 222 had documented results for both smear microscopy 
and Xpert (Table 5). Results were concordant for 204 (92%) pa-
tients; for 13 (6%) smear and Xpert were positive, while for 191 
(94%) both smear and Xpert were negative. All patients with posi-
tive results for both tests were diagnosed with PTB. Of those with a 
negative smear and a negative Xpert test, 153 (80%) were not diag-
nosed with TB, four (2%) were diagnosed with EPTB and 34 (18%) 
were diagnosed with PTB. There were no culture results for these 
34 patients, but 32 (94%) had CXR findings consistent with TB.
There were 18 discordant results between smear microscopy 
and Xpert, including eight (44%) patients with a positive smear 
and negative Xpert, eight (44%) with a negative smear and a posi-
tive Xpert and two (11%) with a negative smear and an invalid 
Xpert. Four (50%) patients with a positive smear and a negative 
Xpert had culture results available; two were found to have NTM 
and two had negative cultures. Of the patients with discordant 
results, 17 (94%) were diagnosed with PTB (Table 5).
TABLE 1 Demographic and baseline clinical characteristics of 
registered PLHA with a positive symptom screen




Age, years, median [IQR] 37 [32–45]
On ART 235 (47)
TB symptoms reported on screening*
 Cough 357 (72)
 Fever 409 (82)
 Weight loss 240 (48)
 2 weeks of night sweats 200 (40)
* Patients were asked about symptoms in the previous month.
PLHA = people living with HIV/AIDS; HIV = human immunodeficiency virus; AIDS = 
acquired immune-deficiency syndrome; IQR = interquartile range; ART = antiretrovi-
ral therapy; TB = tuberculosis.















March† 22 0/8 (0) 2/8 (25) 0/0 0/0
April–June 201 12/147 (8) 46/163 (28) 3/10 (30) 12/46 (26)
July–September 159 9/113 (8) 33/129 (26) 0/7 (0) 4/120 (3)
October–December 115 10/89 (11) 22/51 (43) 1/5 (20) 9/84 (11)
 Total 497 31/357 (9) 103/351 (29) 4/22 (18) 25/250 (10)
* CXR+ = CXR consistent with TB per clinician.
† The PLHA TB Suspect Registers were introduced in March 2012.
TB = tuberculosis; PLHA = people living with HIV/AIDS; AFB = acid-fast bacilli; + = positive; CXR = chest radiograph.
TABLE 3 Xpert results among PLHA with a positive symptom 
screen
n (%)
M. tuberculosis-positive, RMP-susceptible 24 (10)
M. tuberculosis-positive, RMP-indeterminate 1 (0)
M. tuberculosis-negative 222 (89)
Invalid/error 3 (1)
 Total Xpert tests 250 
PHLA = people living with HIV/AIDS; RMP = rifampicin.
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Limitations
Our evaluation was limited to districts offering TB and HIV ser-
vices; the experience of these districts may not address issues spe-
cific to districts without existing clinical TB-HIV services or reflect 
the capacity of other provincial referral hospitals. This evaluation 
relied on routinely collected program data from CENAT registers, 
limiting our ability to determine whether incomplete data re-
flected incomplete testing or poor documentation. Very few pa-
tients underwent culture, limiting our ability to determine the in-
cremental yield of Xpert over smear microscopy among 
culture-confirmed patients.
DISCUSSION
This evaluation identified a number of health system factors that 
may affect the impact of Xpert on patient care in northwest 
Cambodia, namely long TATs at some sites, low utilization of 
Xpert and high rates of empiric treatment. Despite the establish-
ment of specimen referral and result-reporting mechanisms, 
many sites experienced delays in Xpert referral and result report-
ing because specimen transport could only be scheduled once a 
week and results were often reported only when additional spec-
imens were delivered. In addition, due to lack of funding and 
personnel, five sites across three provinces experienced interrup-
tions in specimen transport during the study period, episodically 
suspending Xpert testing. Where onsite testing was available, 
the TAT was often rapid and utilization rates high; however, 
even when Xpert was available on site, delays in collecting speci-
mens from patients resulted in TATs of several days. While the 
utilization of Xpert increased over the course of the evaluation 
to 75% of eligible PLHA by the end of 2012, Xpert use varied 
widely across districts and did not replace smear microscopy as 
the initial test for most patients. Ultimately, only 3% of all eligi-
ble PLHA underwent Xpert as the initial diagnostic in accor-
dance with national guidelines. Additional training and educa-
tion for TB officers and clinicians in the new diagnostic 
algorithm and in reducing TATs could improve the utilization 
and yield of Xpert.
One suggested remedy for long TATs has been to further de-
centralize Xpert, placing more machines at patient point-of-care.8 
However, given the current low utilization rates at central sites, 
the added cost of placing machines in areas where they may not 
be used to capacity may lead to a higher cost per patient.9,10,17,24 
Cambodia has also explored ACF campaigns to increase access; 
such strategies have had variable yield and may not be sustain-
able for PLHA through routine service.17–19 Depending on place-
ment, utilization, and screening and diagnostic algorithms, Xpert 
can increase the cost per case of diagnosed TB by as much as 
US$28–151 in some settings.24 Such costs must be weighed 
against the increased yield of case-finding efforts and the impact 
on patient outcomes to determine its desirability. A cost effective-
ness analysis of Xpert in Cambodia is underway to explore per-pa-
TABLE 4 Xpert testing and turnaround time for PLHA with a positive symptom screen from 
clinic visit date until the Xpert result was returned to the clinic
District
Xpert tests/






Battambang† 39/92 (42) 7 0–16 [1–8]
Sampov Loun 4/14 (29) 5 N/A
Mong Russey 25/53 (47) 17 0–104 [9–35]
Thmar Khoul 17/20 (85) 6 0–24 [3–12]
Mongkol Borei†‡ 161/256 (63) 0 0–35 [0–1]
Thmar Puok 1/10 (10) N/A N/A
Sampov Meas 3/46 (7) 22 N/A
Pailin 0/6 (0) N/A N/A
 All 250/497 (50) 1 0–104 [0–7]
* Of 250 Xpert tests, the date the Xpert result was received by the clinical site was documented for 209 (84%) 
patients.
† Health facilities in these operational districts were co-located with a laboratory performing Xpert testing.
‡ Mongkol Borei district houses two facilities providing TB services for PLHA: Mongkol Borei Referral Hospital and 
Serei Siphon District Referral Hospital.
PLHA = people living with HIV/AIDS; TAT = turnaround time; IQR = interquartile range; N/A = not applicable.
TABLE 5 Diagnostic results by final diagnosis: AFB sputum smear microscopy and Xpert results among the 222 eligible PLHA 



















Not TB 0 0 0 153 (80.1) 1 (50) 154 (69.4)
AFB+ PTB 13 (100) 8 (100) 5 (62.5) 0 0 26 (11.7)
AFB– PTB 0 0 3 (37.5) 34 (17.8) 1 (50) 38 (17.1)
EPTB 0 0 0 4 (2.1) 0 4 (1.8)
 Total 13 8 8 191 2 222
* Among 417 patients with a documented final diagnosis, only 222 had documented results for both sputum smear microscopy and Xpert.
AFB = acid-fast bacilli; PLHA = people living with HIV/AIDS; HIV = human immunodeficiency virus; AIDS = acquired immune-deficiency syndrome; + = posi-
tive; – = negative; TB = tuberculosis; PTB = pulmonary tuberculosis; EPTB = extra-pulmonary tuberculosis.
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tient costs of pre- and post-Xpert algorithms to inform future 
placement and testing strategies.
This evaluation found that empiric treatment for TB was high 
among patients without bacteriological confirmation of TB 
through Xpert or smear microscopy, as well as patients with dis-
cordant Xpert and smear microscopy results. Discordant results 
may reflect errors in the preparation and interpretation of slides, 
or inter-specimen variability, because smear and Xpert testing 
were often performed on different sputum specimens. The limited 
use of culture in routine practice precluded the determination of 
the yield of Xpert in identifying additional smear-negative TB 
cases. In addition, all patients with a positive smear and negative 
Xpert were diagnosed and treated as smear-positive PTB cases, 
which may indicate overtreatment of persons without active TB 
disease. This evaluation and previous reports25 have found high 
rates of NTM in Cambodia, underscoring that Xpert may be a bet-
ter initial diagnostic test than smear microscopy. The high sensi-
tivity and specificity of Xpert over smear microscopy should en-
able the identification of additional, smear-negative cases and a 
reduction in unnecessary empiric treatment. However, these ben-
efits may be attenuated in environments such as Cambodia with 
high rates of empiric treatment.26,27
CONCLUSION
Xpert offers an opportunity for timely and accurate initiation of an-
ti-tuberculosis treatment in Cambodia and other high-burden set-
tings. However, underutilization of Xpert, long turnaround times, 
and use of Xpert as a follow-on diagnostic may undermine the ben-
efit of timely results with Xpert, particularly among PLHA who are 
at increased risk of death with a delayed TB diagnosis.28 Strong 
health systems are imperative to realize the potential of Xpert, in-
cluding robust specimen referral and result-reporting systems, selec-
tion of appropriate testing strategies, and careful placement of ma-
chines where they are both accessible and cost-effective.
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Objectif  :  Décrire la mise en œuvre et l’utilisation du test Xpert(R) 
MTB/RIF afin de diagnostiquer la tuberculose (TB) parmi des personnes 
vivant avec le VIH/SIDA (virus de l’immunodéficience humaine/
syndrome de l’immunodéficience acquise ; PLHA) au Cambodge.
Schéma  :  Après le déploiement du test Xpert, une évaluation a été 
réalisée dans quatre provinces du Cambodge entre mars et décembre 
2012 afin de déterminer l’utilisation, la performance et le délai 
d’exécution du Xpert parmi les PLHA. Des données ont été recueillies 
à partir des dossiers papiers des patients.
Résultats  :  Sur 497 PLHA ayant une grille de symptômes de TB 
positive, 357 (72%) ont bénéficié d’une microscopie de frottis et 250 
(50%) ont eu un test Xpert ; 25 (10%) PLHA testés par Xpert étaient 
positifs pour la TB et aucun n’était résistant à la rifampicine. 
L’utilisation du Xpert est passée de 23% à 75% avec un délai 
d’exécution médian d’un jour. Dans les districts, l’utilisation allait de 
zéro à 85% et le délai de mise en œuvre allait de zéro à 22 jours.
Conclusion  :  Si les données précoces montrent une utilisation 
croissante du Xpert chez les PLHA avec une grille de symptômes 
positive, la majorité des patients bénéficiait initialement d’un 
diagnostic par examen microscopique de frottis. Les délais de 
formation et les problèmes posés par l’envoi des spécimens peuvent 
avoir contribué à la variabilité du recours au Xpert et au délai de sa 
mise en œuvre, particulièrement dans les endroits dépourvus de 
possibilité de test Xpert sur place. Davantage de soutien aux 
programmes, notamment en termes d’envoi des spécimens et de 
retour des résultats, pourrait faciliter son utilisation appropriée.
Objetivo: Describir la introducción y la utilización de la prueba 
Xpert(R) MTB/RIF en el diagnóstico de la tuberculosis (TB) de las 
personas aquejadas de infección por el virus de la inmunodeficiencia 
humana (VIH) y sida (PLHA) en Camboya.
Método: Tras el despliegue de Xpert, se llevó a cabo una evaluación 
en cuatro provincias de Camboya de marzo a diciembre del 2012 
con el fin de determinar el tipo de utilización, el rendimiento 
diagnóstico y el tiempo de obtención de los resultados de la prueba 
Xpert en las PLHA. Se recogieron los datos de los pacientes a partir de 
los registros en soporte de papel.
Resultados: De los 497 PLHA y una detección positiva de síntomas 
de la TB, en 357 casos se practicó una baciloscopia (72%) y en 250 la 
Xpert (50%); 25 de las personas examinadas con Xpert obtuvieron 
un resultado positivo (10%) y en ninguna se observó resistencia a 
rifampicina. La utilización de la prueba aumentó de 23% a 75% y la 
mediana del lapso hasta obtener el resultado fue un día. En los 
diferentes distritos, el uso de la prueba osciló entre 0% y 85% y el 
lapso hasta la notificación del resultado fue de cero a 22 días.
Conclusión: Los datos iniciales indicaron un aumento de la 
utilización de la prueba Xpert en las PLHA que presentan una 
detección positiva de síntomas de la TB, pero en la mayoría de los 
pacientes se practicó la baciloscopia del esputo como prueba 
diagnóstica inicial. Es posible que los retrasos en la capacitación y las 
dificultades relacionadas con la remisión de las muestras hayan 
contribuido a la variabilidad en la aceptación de la Xpert y en el 
tiempo de obtención de los resultados, sobre todo en los centros 
donde no se practica la prueba en el lugar de atención. Se podría 
fomentar el uso apropiado de esta prueba mediante un apoyo 
programático, dirigido especialmente a la remisión de las muestras y 
la notificación de los resultados.
